Literature DB >> 16961667

Clinical aspects of parvovirus B19 infection.

K Broliden1, T Tolfvenstam, O Norbeck.   

Abstract

Parvovirus B19 is a significant human pathogen that causes a wide spectrum of clinical complications ranging from mild, self-limiting erythema infectiosum in immunocompetent children to lethal cytopenias in immunocompromised patients and intrauterine foetal death in primary infected pregnant women. The infection may also be persistent and can mimic or trigger autoimmune inflammatory disorders. Another important clinical aspect to consider is the risk of infection through B19-contaminated blood products. Recent advances in diagnosis and pathogenesis, new insights in the cellular immune response and newly discovered genotypes of human parvoviruses form a platform for the development of modern therapeutic and prophylactic alternatives.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961667     DOI: 10.1111/j.1365-2796.2006.01697.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  50 in total

1.  Parainfectious myelitis associated with parvovirus B19 infection.

Authors:  Franziska Scheibe; Jörg Hofmann; Klemens Ruprecht
Journal:  J Neurol       Date:  2010-03-26       Impact factor: 4.849

Review 2.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

3.  Parvovirus infection mimicking systemic lupus erythematosus.

Authors:  Mohan Cooray; Joshua J Manolakos; Douglas S Wright; Shariq Haider; Ameen Patel
Journal:  CMAJ       Date:  2013-08-26       Impact factor: 8.262

4.  Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation.

Authors:  Mikael Sundin; Anna Lindblom; Claes Örvell; A John Barrett; Berit Sundberg; Emma Watz; Agneta Wikman; Kristina Broliden; Katarina Le Blanc
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

Review 5.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

6.  Central nervous system Richter's transformation and parvovirus B19 infection.

Authors:  Preetesh Jain; Ohad Benjamini; Lin Pei; Nancy P Caraway; Gene Landon; Stella Kim; Sheetal Shivaprasad; Karin Woodman; Susan O'Brien; Alessandra Ferrajoli; Tapan Kadia; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2013-03-04

7.  Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

Authors:  Kristina von Kietzell; Tanja Pozzuto; Regine Heilbronn; Tobias Grössl; Henry Fechner; Stefan Weger
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

8.  Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection.

Authors:  J Mossong; N Hens; V Friederichs; I Davidkin; M Broman; B Litwinska; J Siennicka; A Trzcinska; P VAN Damme; P Beutels; A Vyse; Z Shkedy; M Aerts; M Massari; G Gabutti
Journal:  Epidemiol Infect       Date:  2007-10-24       Impact factor: 2.451

9.  Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication.

Authors:  Claudia Bönsch; Christoph Kempf; Ivo Mueller; Laurens Manning; Moses Laman; Timothy M E Davis; Carlos Ros
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

10.  Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence.

Authors:  Claudia Filippone; Rauli Franssila; Arun Kumar; Leena Saikko; Panu E Kovanen; Maria Söderlund-Venermo; Klaus Hedman
Journal:  PLoS One       Date:  2010-03-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.